Medicare AdvantageCoverageMedium impact
MA08.128, Collagenase clostridium histolyticum ( Xiaflex ®), collagenase clostridium histolyticum-aaes (Qwo®)
Independence Blue Cross·Dermatology, Plastic Surgery, Urology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.128 for collagenase clostridium histolyticum drugs (Xiaflex® and Qwo®) has been reissued and will take effect May 28, 2025. This is a pharmacy policy update that may affect coverage or billing requirements for these specialized injectable treatments.
Action Required
Before May 28, 2025: Billing team should review the full policy details at the source URL to understand any changes to coverage, prior authorization requirements, or billing procedures for Xiaflex® and Qwo® injections. Update billing protocols and staff training as needed based on the complete policy requirements.